SEK 0.01
(5.88%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -29.07 Million SEK | 37.74% |
2022 | -46.69 Million SEK | 9.54% |
2021 | -51.61 Million SEK | -66.53% |
2020 | -30.99 Million SEK | -197.23% |
2019 | -10.42 Million SEK | -47.11% |
2018 | -7.08 Million SEK | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 Q3 | -6.02 Million SEK | 8.71% |
2023 Q4 | -7.51 Million SEK | -24.68% |
2023 Q1 | -11.3 Million SEK | -21.55% |
2023 Q2 | -6.6 Million SEK | 41.6% |
2023 FY | -34.01 Million SEK | 27.16% |
2022 Q3 | -15.77 Million SEK | -48.78% |
2022 Q4 | -9.29 Million SEK | 41.07% |
2022 Q2 | -10.6 Million SEK | 3.69% |
2022 Q1 | -11.01 Million SEK | 2.03% |
2022 FY | -46.69 Million SEK | 9.54% |
2021 Q1 | -12.5 Million SEK | 9.76% |
2021 Q4 | -11.23 Million SEK | -10.07% |
2021 Q3 | -10.21 Million SEK | 42.2% |
2021 Q2 | -17.66 Million SEK | -41.33% |
2021 FY | -51.61 Million SEK | -66.53% |
2020 FY | -30.99 Million SEK | -197.23% |
2020 Q4 | -13.85 Million SEK | -130.98% |
2020 Q3 | -5.99 Million SEK | -14.03% |
2020 Q2 | -5.25 Million SEK | 10.67% |
2020 Q1 | -5.88 Million SEK | 0.0% |
2019 FY | -10.42 Million SEK | -47.11% |
2018 FY | -7.08 Million SEK | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Alligator Bioscience AB (publ) | -248.98 Million SEK | 88.323% |
Ziccum AB (publ) | -21.56 Million SEK | -34.847% |
Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -77.264% |
BioArctic AB (publ) | 252.64 Million SEK | 111.508% |
Sprint Bioscience AB (publ) | -845 Thousand SEK | -3340.592% |
Mendus AB (publ) | -100.65 Million SEK | 71.115% |
Genovis AB (publ.) | 54.22 Million SEK | 153.616% |
Intervacc AB (publ) | -93.57 Million SEK | 68.932% |
QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -87.423% |
Active Biotech AB (publ) | -46.48 Million SEK | 37.456% |
Magle Chemoswed Holding AB (publ) | 18 Million SEK | 261.436% |
Bio-Works Technologies AB (publ) | -55.41 Million SEK | 47.538% |
Aptahem AB (publ) | -10.1 Million SEK | -187.716% |
Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 90.957% |
Kancera AB (publ) | -65.04 Million SEK | 55.301% |
Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 78.403% |
Fluicell AB (publ) | -26.87 Million SEK | -8.163% |
Saniona AB (publ) | -81.06 Million SEK | 64.136% |
Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -135.009% |
Biovica International AB (publ) | -126.07 Million SEK | 76.94% |
Spago Nanomedical AB (publ) | -42.5 Million SEK | 31.601% |
AcouSort AB (publ) | -17.48 Million SEK | -66.255% |
Xintela AB (publ) | -57.23 Million SEK | 49.207% |
Abliva AB (publ) | -96.54 Million SEK | 69.888% |
Egetis Therapeutics AB (publ) | -324.8 Million SEK | 91.049% |
Karolinska Development AB (publ) | -3.5 Million SEK | -729.472% |
OncoZenge AB (publ) | -15.9 Million SEK | -82.826% |
2cureX AB (publ) | -36.36 Million SEK | 20.048% |
CombiGene AB (publ) | -36.3 Million SEK | 19.92% |
Asarina Pharma AB (publ) | -14.64 Million SEK | -98.586% |
Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 92.437% |
Camurus AB (publ) | 532.35 Million SEK | 105.461% |
Corline Biomedical AB | -1.78 Million SEK | -1526.007% |
IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 83.917% |
Isofol Medical AB (publ) | -41.68 Million SEK | 30.252% |
I-Tech AB | 24.43 Million SEK | 218.981% |
Hansa Biopharma AB (publ) | -788.49 Million SEK | 96.313% |
Cyxone AB (publ) | -21.66 Million SEK | -34.218% |
ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 72.564% |
Biosergen AB | -27.26 Million SEK | -6.631% |
Cantargia AB (publ) | -290.01 Million SEK | 89.975% |
NextCell Pharma AB | -43.17 Million SEK | 32.658% |
Xspray Pharma AB (publ) | -180.76 Million SEK | 83.917% |
Elicera Therapeutics AB (publ) | -17.09 Million SEK | -70.055% |
Nanologica AB (publ) | -69.96 Million SEK | 58.445% |
SynAct Pharma AB | -224.49 Million SEK | 87.05% |
Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 34.188% |
Stayble Therapeutics AB (publ) | -23.95 Million SEK | -21.369% |
LIDDS AB (publ) | -40.67 Million SEK | 28.522% |
Lipum AB (publ) | -37.25 Million SEK | 21.96% |
BioInvent International AB (publ) | -369.94 Million SEK | 92.141% |
Alzinova AB (publ) | -16.52 Million SEK | -75.965% |
Oncopeptides AB (publ) | -253.44 Million SEK | 88.529% |
Pila Pharma AB (publ) | -6.39 Million SEK | -354.745% |
Guard Therapeutics International AB (publ) | -115.07 Million SEK | 74.735% |
Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -44.362% |
Simris Alg AB (publ) | -36.63 Million SEK | 20.641% |
Diamyd Medical AB (publ) | -146.56 Million SEK | 80.164% |
Xbrane Biopharma AB (publ) | -310.42 Million SEK | 90.634% |
Ascelia Pharma AB (publ) | -110.91 Million SEK | 73.788% |
Diagonal Bio AB (publ) | -11.56 Million SEK | -151.366% |